CME credits: 0.50 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Jo…

CME credits: 1.00 Valid until: 26-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-resistance-to-response-evolving-strategies-in-mdd-management/32847/ Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel t…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-directions-in-fsgs-care/37191/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-fsgs-traditional-and-novel-biomarkers/37187/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standa…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-considerations-for-pediatric-patients-with-fsgs/37189/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment a…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-fsgs-treatment-landscape-more-questions-than-answers/37184/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatmen…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-the-patient-voice-in-fsgs-management/37190/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standa…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current …

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-interpretation-of-proteinuria-reduction-thresholds/37185/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/ Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammat…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-when-solutions-fall-short/37183/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Anatomical-Outcomes-from-the-LIGHTSITE-III-Trial/35947/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researcher…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Best-Practices-for-Optimized-Photobiomodulation-Treatment-Effect-Candidate-Selection/35949/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Photobiomodulation-A-Non-Invasive-Treatment-for-Ocular-Disease-and-Trauma/35945/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hea…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Patient-Centered-Care-and-Integration-of-Photobiomodulation-Therapy-into-Clinical-Practice/35950/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degene…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Real-World-Evidence-of-Photobiomodulation-Efficacy-in-Ocular-Indications/35952/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Clinical-and-Safety-Outcomes-from-the-LIGHTSITE-III-Trial/35946/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading r…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Sustaining-Visual-Benefits-of-Photobiomodulation-in-Dry-Age-Related-Macular-Degeneration/35948/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degenera…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Integration-of-Photobiomodulation-Therapy-into-the-Age-Related-Macular-Degeneration-Treatment-Landscape/35951/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related m…

CME credits: 1.00 Valid until: 12-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-care-for-crswnp-expert-and-patient-insights/36695/ Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join…

CME credits: 0.50 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Insights-and-Updates-New-Data-on-Next-Generation-Retinal-Treatments/36107/ Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data ar…

CME credits: 0.25 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Retina-Case-Review-Translating-the-Data-Into-Care/36108/ Wondering how your practice’s use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents…

CME credits: 0.25 Valid until: 29-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/ Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell c…

CME credits: 1.00 Valid until: 28-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/ Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitatio…

CME credits: 0.25 Valid until: 27-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-igan-care-achieving-lower-proteinuria-targets-with-combination-therapy/26631/ In this episode of Clinical Countdown, Professors Jonathan Barratt and Sydney Tang discuss the evolving treatment strategies for IgA nephropathy, focusing on low…

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative i…

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-in-the-perioperative-setting/36635/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative …

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative imm…

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/rationale-for-combining-radiation-and-immunotherapy-in-resectable-locally-advanced-hnscc/36592/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integrat…

CME credits: 0.25 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/resectable-head-neck-cancer-a-team-based-approach-to-perioperative-immunotherapy/35705/ Join our expert panel as they explore the evolving treatment landscape of resectable locally advanced head and neck squamous cell carcinoma. Learn how perioperati…

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-collaboration-facilitates-multimodality-therapy/36636/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative im…

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-landscape-of-resectable-locally-advanced-hnscc/36576/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune c…

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-perioperative-icis-in-clinical-practice/36634/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint i…

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/safety-first-navigating-celmod-associated-toxicities/36571/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual…

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-application-unlocking-relapsedrefractory-myeloma-with-celmods/36574/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, wit…

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/real-world-ready-practical-tips-for-community-oncologists/36572/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eve…

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/next-generation-innovations-the-future-of-celmods-in-myeloma/36575/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the …

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/molecular-magic-decoding-the-unique-mechanism-of-celmods/36562/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the even…

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/mastering-the-sequence-celmods-across-treatment-lines/36570/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventua…

CME credits: 0.50 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-reduction-with-glp-1-ras-in-individuals-with-ascvd-and-t2d-2025-update/36474/ Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recomm…

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-application-frontline-insightstackling-newly-diagnosed-myeloma/36573/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, wi…